These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17973783)

  • 1. CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma.
    Konjević G; Jović V; Vuletić A; Radulović S; Jelić S; Spuzić I
    Eur J Clin Invest; 2007 Nov; 37(11):887-96. PubMed ID: 17973783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation between functional capability and phenotypic characteristics of peripheral blood lymphocytes in patients with malignant melanoma].
    Konjević G; Jović V; Radomirović V; Spuzić I
    Glas Srp Akad Nauka Med; 2002; (47):121-36. PubMed ID: 16078447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.
    Konjević G; Jović V; Jurisić V; Radulović S; Jelić S; Spuzić I
    Clin Exp Metastasis; 2003; 20(7):647-55. PubMed ID: 14669796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
    Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
    Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
    Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-γ production in patients with active disease.
    Hervier B; Beziat V; Haroche J; Mathian A; Lebon P; Ghillani-Dalbin P; Musset L; Debré P; Amoura Z; Vieillard V
    Arthritis Rheum; 2011 Jun; 63(6):1698-706. PubMed ID: 21370226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
    Punt CJ; Suciu S; Gore MA; Koller J; Kruit WH; Thomas J; Patel P; Lienard D; Eggermont AM; Keilholz U
    Eur J Cancer; 2006 Nov; 42(17):2991-5. PubMed ID: 17023156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells.
    Clausen J; Vergeiner B; Enk M; Petzer AL; Gastl G; Gunsilius E
    Immunobiology; 2003; 207(2):85-93. PubMed ID: 12675266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
    Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotypic profiles of peripheral blood lymphocytes on the day of embryo transfer in women undergoing in vitro fertilization.
    Baczkowski T; Kurzawa R
    Folia Histochem Cytobiol; 2007; 45 Suppl 1():S73-7. PubMed ID: 18292839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detailed analysis of peripheral blood natural killer (NK) cells in women with recurrent miscarriage.
    King K; Smith S; Chapman M; Sacks G
    Hum Reprod; 2010 Jan; 25(1):52-8. PubMed ID: 19819893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro increased natural killer cell activity of metastatic melanoma patients with interferon-α alone as opposed to its combination with 13-cis retinoic acid is associated with modulation of NKG2D and CD161 activating receptor expression.
    Konjevic G; Mirjacic-Martinovic K; Vuletic A; Babovic N
    J BUON; 2012; 17(4):761-9. PubMed ID: 23335538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The stage dependent changes in NK cell activity and the expression of activating and inhibitory NK cell receptors in melanoma patients.
    Mirjačić Martinović K; Konjević G; Babović N; Inić M
    J Surg Res; 2011 Dec; 171(2):637-49. PubMed ID: 20828749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective induction of melanoma-antigen-specific CD8+ T cells via Vγ9γδT cell expansion by CD56(high+) Interferon-α-induced dendritic cells.
    Nieda M; Terunuma H; Eiraku Y; Deng X; Nicol AJ
    Exp Dermatol; 2015 Jan; 24(1):35-41. PubMed ID: 25363560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune response in blood and tumour tissue in patients with metastatic malignant melanoma treated with IL-2, IFN alpha and histamine dihydrochloride.
    Jørkov AS; Donskov F; Steiniche T; Ternesten-Bratel A; Naredi P; Hellstrand K; Hokland M
    Anticancer Res; 2003; 23(1B):537-42. PubMed ID: 12680142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human liver-resident CD56(bright)/CD16(neg) NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways.
    Hudspeth K; Donadon M; Cimino M; Pontarini E; Tentorio P; Preti M; Hong M; Bertoletti A; Bicciato S; Invernizzi P; Lugli E; Torzilli G; Gershwin ME; Mavilio D
    J Autoimmun; 2016 Jan; 66():40-50. PubMed ID: 26330348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection.
    Lin AW; Gonzalez SA; Cunningham-Rundles S; Dorante G; Marshall S; Tignor A; Ha C; Jacobson IM; Talal AH
    Clin Exp Immunol; 2004 Aug; 137(2):408-16. PubMed ID: 15270860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer receptors on CD8 T cells and natural killer cells from different HLA-C phenotypes in melanoma patients.
    Campillo JA; Martínez-Escribano JA; Moya-Quiles MR; Marín LA; Muro M; Guerra N; Parrado A; Campos M; Frías JF; Minguela A; García-Alonso AM; Alvarez-López MR
    Clin Cancer Res; 2006 Aug; 12(16):4822-31. PubMed ID: 16914567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.